Small Cap Feast
Small Cap Feast – 02nd March 2017
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
BiopPharmma Credit—Targeting $300m + raise on LSE. “This investment trust will give investors access to debt investments tied to the fast growing life sciences industry, offering predictable cash flows over a sustained period of time.” Admission due 27 Mar.
Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
Anglo African Oil & Gas— Admission expected early March. Acquiring stake in producing near offshore field in the Republic of the Congo.
Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Admission due 7 March
First Derivatives (FDP.L) 2288p £569m
The provider of products and consulting services to some of the world’s largest finance, technology and energy institutions has signed a contract with a Fortune 500 engineering solutions company for the use of its Kx technology within precision manufacturing. Kx has been selected as the high-performance, time-series data historian and analytics platform in the next version of the client’s fault detection product range, expected to be released in mid-2017. The total expected value over a five year period places this contract amongst some of the larger software contracts FD has signed. FYFeb18E PE of 38.7x and 0.9% yield.
Field Systems Designs (NEX:FSD) 26.5p £1.5m
The specialist installation and engineering Group providing mechanical and electrical installation and maintenance services in the water, power, waste, security, commercial and transport industries has reported HYNov16 results. Rev £8.5m from £8.3m. PBT of £92k from £68k. Cash of £2.3m. ‘The Board expect volumes in the water sector to continue to improve, but the timing of release of Energy from Waste work is difficult to predict. The order book however remains strong and the balance sheet sound. The directors believe that the group remains well positioned for the future.’
Base Resources (BSE.L) 17.625p £130.8m
Preliminary exploration results. Additional mineralisation discovered that extends the footprint of the Kwale South Dune Deposit to the south by 950m and east by up to a further 500m. Discovery of a new dunal mineral deposit at Mafisini, a continuation of the Kwale South Dune Deposit mineralisation, with recorded intercepts over a contiguous 1240m of strike and up to 480m in width. Discovery of new dunal mineralisation and marine sediments in the NE Sector, adjacent to the Kwale Central Dune. Visual inspection of the Kwale South Dune Deposit extension and Mafisini Deposit mineralisation indicates a similar composition and high-value mineralogy as that reported for the Kwale Operations Mineral Resources (134.6Mt at 4.2% heavy mineral (“HM”), 26% slimes, 2% oversize and a HM assemblage of 59% ilmenite, 13% rutile and 6% zircon.)
Morses Club (MCL.L) 118p £152.8m
FY Feb 17 trading update from the UK’s second largest home collected credit lender. Trading performance for the period has continued to show strong growth and is in line with the Board’s expectations. Total credit issued increased by 18% to £144m compared with the prior year, with customer numbers increasing by 9% to 216,000 as at 25 February 2017. This increase reflects the success of new territory builds and acquisitions in our core home collect credit market. The Company’s gross loan book is up over 4% compared with 27 February 2016. The proportion of loans attributable to highest tier customers has increased by 10% against last year, demonstrating the Company’s focus on higher quality lending. Acquired Shelby Finance in Jan 17 and is finalising plans for the launch of its new online instalment lending product.
HML Holdings (HML.L) 41.5p £18.5m
The provider of property management, insurance and ancillary services to residential property blocks, announced the acquisition of the Block Management Business of Gordon and Company Property Consultants Limited, the flats and estates property management business of Gordon & Company. Initial £1m consideration and £0.4m earn-out. The acquisition produces normalised annual revenues of £1.1 million. It is expected that G&CPCL will be earnings enhancing once it has been fully integrated into HML. FYMar17E rev of £20.3m and PBT of £1.8m
Molins (MLIN.L) 68p £13.7m
FYDec16 results from the specialist in the design, development and manufacture of secondary tobacco processing machinery. Sales: £80.1m (2015: £87.0m). Underlying PBT: £0.9m (2015: £3.8m). Statutory pre-tax loss: £0.8m (2015: £2.0m profit from continuing ops). No final divi. Increase in order intake of 20% and significantly higher order book at start of 2017. “Molins has presence in large and attractive growth markets, an enviable portfolio of global multinational customers, an impressive range of innovative technologies and above all a very talented and engaged workforce. With the implementation of the strategic review findings, I am confident we have significant potential to grow.”
Total Produce (TOT.L) 159p £508m
The fresh produce provider has reported FY December 2016 results. Revenue up 8.9% to €3.76 billion. Adjusted fully diluted EPS up 14.1% to 12.07 cents. Adjusted EBITDA up 14.5% to €94.8m. “We are pleased to propose a 10% increase in final dividend to 2.2297 cent per share. The Group is continuing to actively pursue additional acquisitions and is targeting 2017 adjusted earnings per share in the range of 12.0 to 13.0 cent per share.”
Diurnal Group (DNL.L) 133.5p £69.7m
The specialty pharmaceutical Company targeting patient needs in chronic endocrine (hormonal) diseases, announced a marketing and distribution agreement with Medison Pharma Ltd (Medison), Israel’s leading group for the marketing of innovative niche healthcare solutions. The agreement covers the commercialisation in Israel of Diurnal’s novel therapies for adrenal insufficiency, Infacort® and Chronocort®. Infacort®is expected to be submitted for marketing authorisation in Israel once approved by the EMA. Diurnal anticipates EMA marketing authorisation approval for Infacort® could come towards the end of 2017 with the potential of approval in Israel during 2018. Mkt opportunity in Israel c. $7m.
Sunrise Resources (SRES.L) 0.12p £1.4m
The diversified mineral exploration and development Company provided a positive update on testwork and details of a new development in the potential commercialisation of the CS Project. Variability testing of samples from across the deposit indicate consistent results as a high quality natural pozzolan. Pozzolan testwork accelerated. Samples now submitted to accredited laboratory for certification testing. Results expected within 45 days. Testing also identified a potentially valuable opportunity for production of Perlite, a product in high demand in the construction and other industries. Concept Study in progress to evaluate commercial options expanded to include perlite production.
Osirium Technologies(OSI.L) 105p £10.9m
The UK based cyber-security software provider, announced that its Privileged Access Management product is now available in the Asia Pacific region (APAC). Additionally, Osirium has appointed Distology as a UK distribution partner. As part of Osirium’s commitment to the APAC, the Group has appointed Hugh Sunderland and Mike Stephens as Business Development Directors for the region. They will have responsibility for identifying and recruiting key value-added distributors and associated business partners. There are no forecasts in the market.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.